journal
https://read.qxmd.com/read/38451539/prospective-data-on-stereotactic-ablative-radiotherapy-provides-guidance-in-an-unusual-clinical-scenario
#21
JOURNAL ARTICLE
Ashley A Weiner, Lawrence B Marks
No abstract text is available yet for this article.
March 7, 2024: JAMA Oncology
https://read.qxmd.com/read/38451536/charting-the-path-to-systemic-therapy-de-escalation-oligometastatic-kidney-cancer-as-a-paradigm
#22
JOURNAL ARTICLE
Chad Tang, Pavlos Msaouel
No abstract text is available yet for this article.
March 7, 2024: JAMA Oncology
https://read.qxmd.com/read/38451530/immunotherapy-or-chemoimmunotherapy-in-older-adults-with-advanced-non-small-cell-lung-cancer
#23
JOURNAL ARTICLE
Yoko Tsukita, Takehiro Tozuka, Kohei Kushiro, Shinobu Hosokawa, Toshiyuki Sumi, Mao Uematsu, Osamu Honjo, Ou Yamaguchi, Tetsuhiko Asao, Jun Sugisaka, Go Saito, Jun Shiihara, Ryo Morita, Seigo Katakura, Takehiro Yasuda, Kakeru Hisakane, Eisaku Miyauchi, Satoshi Morita, Kunihiko Kobayashi, Hajime Asahina
IMPORTANCE: Immune checkpoint inhibitor (ICI) plus chemotherapy combination treatment (ICI-chemotherapy) is now a standard treatment for non-small cell lung cancer (NSCLC) without targetable oncogene alterations, but there are few data on ICI-chemotherapy for patients 75 years and older. OBJECTIVE: To inform the choice of first-line drugs in clinical practice and assess the safety and efficacy of ICI-chemotherapy combination treatment in older adult patients with previously untreated advanced NSCLC...
March 7, 2024: JAMA Oncology
https://read.qxmd.com/read/38451519/advancing-truth-in-oncology-by-complementing-clinical-trials-with-evidence-from-clinical-practice
#24
JOURNAL ARTICLE
Elad Sharon
No abstract text is available yet for this article.
March 7, 2024: JAMA Oncology
https://read.qxmd.com/read/38451492/efficacy-and-safety-of-radiotherapy-plus-relugolix-in-men-with-localized-or-advanced-prostate-cancer
#25
JOURNAL ARTICLE
Daniel E Spratt, Daniel J George, Neal D Shore, Michael S Cookson, Daniel R Saltzstein, Ronald Tutrone, Alberto Bossi, Bruce A Brown, Sophia Lu, Mark Fallick, Sarah Hanson, Bertrand F Tombal
IMPORTANCE: Combination androgen deprivation therapy (ADT) with radiotherapy is commonly used for patients with localized and advanced prostate cancer. OBJECTIVE: To assess the efficacy and safety of the oral gonadotropin-releasing hormone antagonist relugolix with radiotherapy for treating prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: This multicenter post hoc analysis of patients with localized and advanced prostate cancer receiving radiotherapy in 2 randomized clinical trials (a phase 2 trial of relugolix vs degarelix, and a subset of the phase 3 HERO trial of relugolix vs leuprolide acetate) included men who were receiving radiotherapy and short-term (24 weeks) ADT (n = 103) from 2014 to 2015 and men receiving radiotherapy and longer-term (48 weeks) ADT (n = 157) from 2017 to 2019...
March 7, 2024: JAMA Oncology
https://read.qxmd.com/read/38451491/stereotactic-radiation-therapy-in-early-non-small-cell-lung-cancer-and-interstitial-lung-disease-a-nonrandomized-clinical-trial
#26
JOURNAL ARTICLE
David A Palma, Houda Bahig, Andrew Hope, Stephen Harrow, Brock J Debenham, Alexander V Louie, Thi Trinh Thuc Toni Vu, Edith Filion, Andrea Bezjak, Marie-Pierre Campeau, Adele Duimering, Meredith E Giuliani, Joanna M Laba, Pencilla Lang, Benjamin H Lok, X Melody Qu, Srinivas Raman, George B Rodrigues, Christopher D Goodman, Stewart Gaede, Julie Morisset, Andrew Warner, Inderdeep Dhaliwal, Christopher J Ryerson
IMPORTANCE: Patients with interstitial lung disease (ILD) and early-stage non-small cell lung cancer (NSCLC) have been reported to be at high risk of toxic effects after stereotactic ablative radiotherapy (SABR), but for many patients, there are limited alternative treatment options. OBJECTIVE: To prospectively assess the benefits and toxic effects of SABR in this patient population. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was conducted at 6 academic radiation oncology institutions, 5 in Canada and 1 in Scotland, with accrual between March 7, 2019, and January 12, 2022...
March 7, 2024: JAMA Oncology
https://read.qxmd.com/read/38421677/bilateral-oophorectomy-and-all-cause-mortality-in-women-with-brca1-and-brca2-sequence-variations
#27
JOURNAL ARTICLE
Joanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, Pål Møller, Tuya Pal, Jeanna M McCuaig, Christian F Singer, Beth Y Karlan, Amber Aeilts, Charis Eng, Andrea Eisen, Louise Bordeleau, William D Foulkes, Nadine Tung, Fergus J Couch, Robert Fruscio, Susan L Neuhausen, Dana Zakalik, Cezary Cybulski, Kelly Metcalfe, Olufunmilayo I Olopade, Ping Sun, Jan Lubinski, Steven A Narod
IMPORTANCE: Preventive bilateral salpingo-oophorectomy is offered to women at high risk of ovarian cancer who carry a pathogenic variant in BRCA1 or BRCA2; however, the association of oophorectomy with all-cause mortality has not been clearly defined. OBJECTIVE: To evaluate the association between bilateral oophorectomy and all-cause mortality among women with a BRCA1 or BRCA2 sequence variation. DESIGN, SETTING, AND PARTICIPANTS: In this international, longitudinal cohort study of women with BRCA sequence variations, information on bilateral oophorectomy was obtained via biennial questionnaire...
February 29, 2024: JAMA Oncology
https://read.qxmd.com/read/38421676/mri-surveillance-and-breast-cancer-mortality-in-women-with-brca1-and-brca2-sequence-variations
#28
JOURNAL ARTICLE
Jan Lubinski, Joanne Kotsopoulos, Pal Moller, Tuya Pal, Andrea Eisen, Larissa Peck, Beth Y Karlan, Amber Aeilts, Charis Eng, Louise Bordeleau, William D Foulkes, Nadine Tung, Fergus J Couch, Robert Fruscio, Teresa Ramon Y Cajal, Christian F Singer, Susan L Neuhausen, Dana Zakalik, Cezary Cybulski, Jacek Gronwald, Tomasz Huzarski, Klaudia Stempa, Jeffrey Dungan, Carey Cullinane, Olufunmilayo I Olopade, Kelly Metcalfe, Ping Sun, Steven A Narod
IMPORTANCE: Magnetic resonance imaging (MRI) surveillance is offered to women with a pathogenic variant in the BRCA1 or BRCA2 gene who face a high lifetime risk of breast cancer. Surveillance with MRI is effective in downstaging breast cancers, but the association of MRI surveillance with mortality risk has not been well defined. OBJECTIVE: To compare breast cancer mortality rates in women with a BRCA1 or BRCA2 sequence variation who entered an MRI surveillance program with those who did not...
February 29, 2024: JAMA Oncology
https://read.qxmd.com/read/38421673/mortality-risks-over-20-years-in-men-with-stage-i-to-iii-hormone-receptor-positive-breast-cancer
#29
JOURNAL ARTICLE
Julieta Leone, Michael J Hassett, Rachel A Freedman, Sara M Tolaney, Noah Graham, Nabihah Tayob, Carlos T Vallejo, Eric P Winer, Nancy U Lin, José P Leone
IMPORTANCE: In women with hormone receptor-positive (HR+) breast cancer, the risk of distant recurrence and death persists for at least 20 years from diagnosis. The risk of late mortality in men with HR+ breast cancer has not been reported. OBJECTIVE: To report 20-year risks of breast cancer-specific mortality (BCSM) and non-BCSM in men with stage I to III HR+ breast cancer and identify factors associated with late BCSM. DESIGN, SETTING, AND PARTICIPANTS: An observational cohort study was conducted of men diagnosed with HR+ breast cancer from 1990 to 2008, using population-based data from the Surveillance, Epidemiology, and End Results program...
February 29, 2024: JAMA Oncology
https://read.qxmd.com/read/38421669/progression-free-survival-analysis-with-a-graphical-estimand-approach-in-the-phase-2-samco-prodige-54-trial-reply
#30
JOURNAL ARTICLE
Olayidé Boussari, Julien Taïeb
No abstract text is available yet for this article.
February 29, 2024: JAMA Oncology
https://read.qxmd.com/read/38421667/increasing-the-uptake-of-cancer-risk-management-strategies-for-women-with-brca1-2-sequence-variations
#31
JOURNAL ARTICLE
Meghna S Trivedi, Katrina A Armstrong
No abstract text is available yet for this article.
February 29, 2024: JAMA Oncology
https://read.qxmd.com/read/38421658/progression-free-survival-analysis-with-a-graphical-estimand-approach-in-the-phase-2-samco-prodige-54-trial
#32
JOURNAL ARTICLE
Yi-Cheng Tai, Weijing Wang, Martin T Wells
No abstract text is available yet for this article.
February 29, 2024: JAMA Oncology
https://read.qxmd.com/read/38421642/error-in-text
#33
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 29, 2024: JAMA Oncology
https://read.qxmd.com/read/38386352/error-in-affiliations
#34
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 22, 2024: JAMA Oncology
https://read.qxmd.com/read/38386344/undiagnosed-cancer-cases-in-the-us-during-the-first-10-months-of-the-covid-19-pandemic
#35
JOURNAL ARTICLE
Todd Burus, Feitong Lei, Bin Huang, W Jay Christian, Pamela C Hull, Amanda R Ellis, Svetla Slavova, Thomas C Tucker, Krystle A Lang Kuhs
IMPORTANCE: The COVID-19 pandemic disrupted the normal course of cancer screening and detection in the US. A nationwide analysis of the extent of this disruption using cancer registry data has not been conducted. OBJECTIVE: To assess the observed and expected cancer rate trends for March through December 2020 using data from all 50 US states and the District of Columbia. DESIGN, SETTINGS, AND PARTICIPANTS: This was a population-based cross-sectional analysis of cancer incidence trends using data on cases of invasive cancer diagnosis reported to the US Cancer Statistics from January 1, 2018, through December 31, 2020...
February 22, 2024: JAMA Oncology
https://read.qxmd.com/read/38386328/accreditation-standards-an-untapped-lever-for-cancer-equity
#36
JOURNAL ARTICLE
Parsa Erfani, Nishant Uppal, Miranda B Lam
No abstract text is available yet for this article.
February 22, 2024: JAMA Oncology
https://read.qxmd.com/read/38386311/features-and-factors-associated-with-myeloid-neoplasms-after-chimeric-antigen-receptor-t-cell-therapy
#37
JOURNAL ARTICLE
Mark Gurney, Anmol Baranwal, Allison Rosenthal, Mohamed A Kharfan-Dabaja, Saad S Kenderian, Yi Lin, Mithun Vinod Shah
No abstract text is available yet for this article.
February 22, 2024: JAMA Oncology
https://read.qxmd.com/read/38358777/considerations-for-prompting-large-language-models-reply
#38
JOURNAL ARTICLE
Shan Chen, Guergana K Savova, Danielle S Bitterman
No abstract text is available yet for this article.
February 15, 2024: JAMA Oncology
https://read.qxmd.com/read/38358775/modernize-precision-oncology-with-decentralized-trial-tools
#39
JOURNAL ARTICLE
Muhammad Shaalan Beg, Vivek Subbiah
No abstract text is available yet for this article.
February 15, 2024: JAMA Oncology
https://read.qxmd.com/read/38358767/error-in-figure
#40
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 15, 2024: JAMA Oncology
journal
journal
50067
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.